Fatal orbital disorder;Potenziell letaler orbitaprozess

Klinische Monatsblatter fur Augenheilkunde

Volumn 221, Issue 11, 2004, Pages 948-952

  Von Eicken, Jörn ^a   Preyer, S ^a   Wilhelm, H ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Immunodeficency; Mucormycosis; Orbital inflammation

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE SEVERITY; FATALITY; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; MICROBIOLOGICAL EXAMINATION; MUCORMYCOSIS; ORBIT DISEASE; RARE DISEASE; SOFT TISSUE; SURGICAL APPROACH;

EID: 10344253306     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813597     Document Type: Article

References (16)

1. Artis WM, Fountain JA, Deicher HK et al. A mechanism of susceptibilitry to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31 (12): 1109-1114
2. Boelaert JR, Fenves AZ, Coburn JW. Mucormycosis among patients on dialysis. N England J Med 1989; 321: 190-191
3. Bohme A, Karthaus M, Hoelzer D. Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit? Chemotherapy 1999; 45: 224-232
4. Burde RM, Savino PJ, Trobe JD. Clinical Decisions in Neuroopthalmology 2002; third edition: 312-324
5. Chakrabarti A, Das A, Sharma A et al. Ten years' experience in zygomycosis at a tertiary care centre in India. J Infect 2001; 42: 2616
6. Chassaing N, Valton L, Kany M et al. Rhino-cerebral fungal infection successfully treated with supplementary hyperbaric oxygen therapy. Rev Neurol 2003; 159 (12): 1178-1180
7. Daly AL, Velazquez LA, Brandley SF et al. Mucormycosis: Association with deferoxamin therapie. Am J Med 1989; 87: 468-471
8. De La Paz MA, Patrinely JR, Marines HM et al. Adjunctive hyperbaric oxygen in the treatment of bilateral cerebro-rhino-orbital Mucormycosis. Am J Ophthalmol 1992; 15 (114-2): 208-211
9. Dooley D, Hollsten D, Grimes S et al. Indolent orbital Apex Syndrome caused by occult Mucormycosis. J Clin Neuroophthalmol 1992; 12 (4): 245-249
10. Ferry AP. Diskussionsbeitrag im Anhang des Artikels: Kohn R, Hepler R. Management of limited rhino-orbital Mucormycosis without exenteration. Ophthalmology 1985; 92: 1440-1444
11. Guoit HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18: 525-532
12. Kohn R, Hepler R. Management of limited rhino-orbital Mucormycosis without exenteration. Ophthalmology 1985; 92: 1440-1444
13. Krcmery VJr, Kunova E, Jesenska Z et al. Invasive mold infections in cancer patients: 5 years' experience with Aspergillus, Mucor, Fusarium, and Acremonium infections. Support Care Cancer 1996; 41: 39-45
14. Pagano LP, Ricci A, Tonso A et al. Mucormycosis in patients with hematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol 1997; 99: 331-336
15. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332
16. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301